Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients
This prospective cohort study within an open‐label, single‐arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698) aimed to investigate the association between physical activity and persistent anti‐SARS‐CoV‐2 antibodies 6 months after two‐dose schedule of CoronaVac in autoimmune rheumatic d...
Gespeichert in:
| Veröffentlicht in: | Scandinavian journal of medicine & science in sports 2022-10, Vol.32 (10), p.1510-1515 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1515 |
|---|---|
| container_issue | 10 |
| container_start_page | 1510 |
| container_title | Scandinavian journal of medicine & science in sports |
| container_volume | 32 |
| creator | Gualano, Bruno Lemes, Ítalo Ribeiro Silva, Rafael Pires Pinto, Ana Jéssica Mazzolani, Bruna Caruso Smaira, Fabiana Infante Sieczkowska, Sofia Mendes Aikawa, Nádia Emi Pasoto, Sandra Medeiros‐Ribeiro, Ana Cristina Saad, Carla Yuk, Emily Silva, Clovis Swinton, Paul Hallal, Pedro Curi Roschel, Hamilton Bonfa, Eloisa |
| description | This prospective cohort study within an open‐label, single‐arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698) aimed to investigate the association between physical activity and persistent anti‐SARS‐CoV‐2 antibodies 6 months after two‐dose schedule of CoronaVac in autoimmune rheumatic diseases (ARD) patients (n = 748). Persistent immunogenicity 6 months after the full‐course vaccination was assessed using seroconversion rates of total anti‐SARS‐CoV‐2 S1/S2 IgG, geometric mean titers of anti‐S1/S2 IgG (GMT), and frequency of positive neutralizing antibodies (NAb). Physical activity was assessed trough questionnaire. Adjusted point estimates from logistic regression models indicated that physically active patients had greater odds of seroconversion rates (OR: 1.5 [95%CI: 1.1 to 2.1]) and NAb positivity (OR: 1.5 [95%CI: 1.0 to 2.1]), and approximately 43% greater GMT (42.8% [95%CI: 11.9 to 82.2]) than inactive ones. In conclusion, among immunocompromised patients, being physically active was associated with an increment in antibody persistence through 6 months after a full‐course of an inactivated SARS‐CoV‐2 vaccine. |
| doi_str_mv | 10.1111/sms.14213 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2691462504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2713150780</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3653-a815f98c4d626c3c4dc74ef6ffb3cec5d05a8db1f026b687c32c6204209800263</originalsourceid><addsrcrecordid>eNp10E2LFDEQBuAgCo6rB_9BwIseereSdKfTRxn8ghWFVa8hk64wWbqTMZVR-t8bHU-CgVBQPAkvL2PPBVyLdm5opWvRS6EesJ3QAB0YZR6yHUwwdKMw5jF7QnQPIMapH3asfj5uFL1buPM1_oh14y7N7dZ4yPPGT1goUsXkkWu-5lSPxF2oWHg9Iif0ufE5E_Ic-D6XnNw353lMPK7rOWWf11PJaySc-cnViKnSU_YouIXw2d95xb6-ffNl_767_fTuw_71beeVHlTnjBjCZHw_a6m9atOPPQYdwkF59MMMgzPzQQSQ-qDN6JX0WkIvYTLQduqKvbz82xJ8PyNV23J4XBaXMJ_JSj2JXssB-kZf_EPv87mkls7KUSgxwGigqVcX5UsmKhjsqcTVlc0KsL_7t61_-6f_Zm8u9mdccPs_tHcf7y4vfgE8_Igp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2713150780</pqid></control><display><type>article</type><title>Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients</title><source>Access via Wiley Online Library</source><creator>Gualano, Bruno ; Lemes, Ítalo Ribeiro ; Silva, Rafael Pires ; Pinto, Ana Jéssica ; Mazzolani, Bruna Caruso ; Smaira, Fabiana Infante ; Sieczkowska, Sofia Mendes ; Aikawa, Nádia Emi ; Pasoto, Sandra ; Medeiros‐Ribeiro, Ana Cristina ; Saad, Carla ; Yuk, Emily ; Silva, Clovis ; Swinton, Paul ; Hallal, Pedro Curi ; Roschel, Hamilton ; Bonfa, Eloisa</creator><creatorcontrib>Gualano, Bruno ; Lemes, Ítalo Ribeiro ; Silva, Rafael Pires ; Pinto, Ana Jéssica ; Mazzolani, Bruna Caruso ; Smaira, Fabiana Infante ; Sieczkowska, Sofia Mendes ; Aikawa, Nádia Emi ; Pasoto, Sandra ; Medeiros‐Ribeiro, Ana Cristina ; Saad, Carla ; Yuk, Emily ; Silva, Clovis ; Swinton, Paul ; Hallal, Pedro Curi ; Roschel, Hamilton ; Bonfa, Eloisa</creatorcontrib><description>This prospective cohort study within an open‐label, single‐arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698) aimed to investigate the association between physical activity and persistent anti‐SARS‐CoV‐2 antibodies 6 months after two‐dose schedule of CoronaVac in autoimmune rheumatic diseases (ARD) patients (n = 748). Persistent immunogenicity 6 months after the full‐course vaccination was assessed using seroconversion rates of total anti‐SARS‐CoV‐2 S1/S2 IgG, geometric mean titers of anti‐S1/S2 IgG (GMT), and frequency of positive neutralizing antibodies (NAb). Physical activity was assessed trough questionnaire. Adjusted point estimates from logistic regression models indicated that physically active patients had greater odds of seroconversion rates (OR: 1.5 [95%CI: 1.1 to 2.1]) and NAb positivity (OR: 1.5 [95%CI: 1.0 to 2.1]), and approximately 43% greater GMT (42.8% [95%CI: 11.9 to 82.2]) than inactive ones. In conclusion, among immunocompromised patients, being physically active was associated with an increment in antibody persistence through 6 months after a full‐course of an inactivated SARS‐CoV‐2 vaccine.</description><identifier>ISSN: 0905-7188</identifier><identifier>EISSN: 1600-0838</identifier><identifier>DOI: 10.1111/sms.14213</identifier><language>eng</language><publisher>Oxford: Blackwell Publishing Ltd</publisher><subject>autoimmune rheumatic disease ; COVID‐19 ; Drug dosages ; Exercise ; immunosuppression ; physical activity ; vaccine responses</subject><ispartof>Scandinavian journal of medicine & science in sports, 2022-10, Vol.32 (10), p.1510-1515</ispartof><rights>2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>Copyright © 2022 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3653-a815f98c4d626c3c4dc74ef6ffb3cec5d05a8db1f026b687c32c6204209800263</citedby><cites>FETCH-LOGICAL-c3653-a815f98c4d626c3c4dc74ef6ffb3cec5d05a8db1f026b687c32c6204209800263</cites><orcidid>0000-0002-0520-4681 ; 0000-0001-9663-0696 ; 0000-0001-7100-8681 ; 0000-0001-9245-287X ; 0000-0003-4218-4779 ; 0000-0003-1470-6461 ; 0000-0002-9513-6132</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fsms.14213$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fsms.14213$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids></links><search><creatorcontrib>Gualano, Bruno</creatorcontrib><creatorcontrib>Lemes, Ítalo Ribeiro</creatorcontrib><creatorcontrib>Silva, Rafael Pires</creatorcontrib><creatorcontrib>Pinto, Ana Jéssica</creatorcontrib><creatorcontrib>Mazzolani, Bruna Caruso</creatorcontrib><creatorcontrib>Smaira, Fabiana Infante</creatorcontrib><creatorcontrib>Sieczkowska, Sofia Mendes</creatorcontrib><creatorcontrib>Aikawa, Nádia Emi</creatorcontrib><creatorcontrib>Pasoto, Sandra</creatorcontrib><creatorcontrib>Medeiros‐Ribeiro, Ana Cristina</creatorcontrib><creatorcontrib>Saad, Carla</creatorcontrib><creatorcontrib>Yuk, Emily</creatorcontrib><creatorcontrib>Silva, Clovis</creatorcontrib><creatorcontrib>Swinton, Paul</creatorcontrib><creatorcontrib>Hallal, Pedro Curi</creatorcontrib><creatorcontrib>Roschel, Hamilton</creatorcontrib><creatorcontrib>Bonfa, Eloisa</creatorcontrib><title>Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients</title><title>Scandinavian journal of medicine & science in sports</title><description>This prospective cohort study within an open‐label, single‐arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698) aimed to investigate the association between physical activity and persistent anti‐SARS‐CoV‐2 antibodies 6 months after two‐dose schedule of CoronaVac in autoimmune rheumatic diseases (ARD) patients (n = 748). Persistent immunogenicity 6 months after the full‐course vaccination was assessed using seroconversion rates of total anti‐SARS‐CoV‐2 S1/S2 IgG, geometric mean titers of anti‐S1/S2 IgG (GMT), and frequency of positive neutralizing antibodies (NAb). Physical activity was assessed trough questionnaire. Adjusted point estimates from logistic regression models indicated that physically active patients had greater odds of seroconversion rates (OR: 1.5 [95%CI: 1.1 to 2.1]) and NAb positivity (OR: 1.5 [95%CI: 1.0 to 2.1]), and approximately 43% greater GMT (42.8% [95%CI: 11.9 to 82.2]) than inactive ones. In conclusion, among immunocompromised patients, being physically active was associated with an increment in antibody persistence through 6 months after a full‐course of an inactivated SARS‐CoV‐2 vaccine.</description><subject>autoimmune rheumatic disease</subject><subject>COVID‐19</subject><subject>Drug dosages</subject><subject>Exercise</subject><subject>immunosuppression</subject><subject>physical activity</subject><subject>vaccine responses</subject><issn>0905-7188</issn><issn>1600-0838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp10E2LFDEQBuAgCo6rB_9BwIseereSdKfTRxn8ghWFVa8hk64wWbqTMZVR-t8bHU-CgVBQPAkvL2PPBVyLdm5opWvRS6EesJ3QAB0YZR6yHUwwdKMw5jF7QnQPIMapH3asfj5uFL1buPM1_oh14y7N7dZ4yPPGT1goUsXkkWu-5lSPxF2oWHg9Iif0ufE5E_Ic-D6XnNw353lMPK7rOWWf11PJaySc-cnViKnSU_YouIXw2d95xb6-ffNl_767_fTuw_71beeVHlTnjBjCZHw_a6m9atOPPQYdwkF59MMMgzPzQQSQ-qDN6JX0WkIvYTLQduqKvbz82xJ8PyNV23J4XBaXMJ_JSj2JXssB-kZf_EPv87mkls7KUSgxwGigqVcX5UsmKhjsqcTVlc0KsL_7t61_-6f_Zm8u9mdccPs_tHcf7y4vfgE8_Igp</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Gualano, Bruno</creator><creator>Lemes, Ítalo Ribeiro</creator><creator>Silva, Rafael Pires</creator><creator>Pinto, Ana Jéssica</creator><creator>Mazzolani, Bruna Caruso</creator><creator>Smaira, Fabiana Infante</creator><creator>Sieczkowska, Sofia Mendes</creator><creator>Aikawa, Nádia Emi</creator><creator>Pasoto, Sandra</creator><creator>Medeiros‐Ribeiro, Ana Cristina</creator><creator>Saad, Carla</creator><creator>Yuk, Emily</creator><creator>Silva, Clovis</creator><creator>Swinton, Paul</creator><creator>Hallal, Pedro Curi</creator><creator>Roschel, Hamilton</creator><creator>Bonfa, Eloisa</creator><general>Blackwell Publishing Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0520-4681</orcidid><orcidid>https://orcid.org/0000-0001-9663-0696</orcidid><orcidid>https://orcid.org/0000-0001-7100-8681</orcidid><orcidid>https://orcid.org/0000-0001-9245-287X</orcidid><orcidid>https://orcid.org/0000-0003-4218-4779</orcidid><orcidid>https://orcid.org/0000-0003-1470-6461</orcidid><orcidid>https://orcid.org/0000-0002-9513-6132</orcidid></search><sort><creationdate>202210</creationdate><title>Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients</title><author>Gualano, Bruno ; Lemes, Ítalo Ribeiro ; Silva, Rafael Pires ; Pinto, Ana Jéssica ; Mazzolani, Bruna Caruso ; Smaira, Fabiana Infante ; Sieczkowska, Sofia Mendes ; Aikawa, Nádia Emi ; Pasoto, Sandra ; Medeiros‐Ribeiro, Ana Cristina ; Saad, Carla ; Yuk, Emily ; Silva, Clovis ; Swinton, Paul ; Hallal, Pedro Curi ; Roschel, Hamilton ; Bonfa, Eloisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3653-a815f98c4d626c3c4dc74ef6ffb3cec5d05a8db1f026b687c32c6204209800263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>autoimmune rheumatic disease</topic><topic>COVID‐19</topic><topic>Drug dosages</topic><topic>Exercise</topic><topic>immunosuppression</topic><topic>physical activity</topic><topic>vaccine responses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gualano, Bruno</creatorcontrib><creatorcontrib>Lemes, Ítalo Ribeiro</creatorcontrib><creatorcontrib>Silva, Rafael Pires</creatorcontrib><creatorcontrib>Pinto, Ana Jéssica</creatorcontrib><creatorcontrib>Mazzolani, Bruna Caruso</creatorcontrib><creatorcontrib>Smaira, Fabiana Infante</creatorcontrib><creatorcontrib>Sieczkowska, Sofia Mendes</creatorcontrib><creatorcontrib>Aikawa, Nádia Emi</creatorcontrib><creatorcontrib>Pasoto, Sandra</creatorcontrib><creatorcontrib>Medeiros‐Ribeiro, Ana Cristina</creatorcontrib><creatorcontrib>Saad, Carla</creatorcontrib><creatorcontrib>Yuk, Emily</creatorcontrib><creatorcontrib>Silva, Clovis</creatorcontrib><creatorcontrib>Swinton, Paul</creatorcontrib><creatorcontrib>Hallal, Pedro Curi</creatorcontrib><creatorcontrib>Roschel, Hamilton</creatorcontrib><creatorcontrib>Bonfa, Eloisa</creatorcontrib><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Scandinavian journal of medicine & science in sports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gualano, Bruno</au><au>Lemes, Ítalo Ribeiro</au><au>Silva, Rafael Pires</au><au>Pinto, Ana Jéssica</au><au>Mazzolani, Bruna Caruso</au><au>Smaira, Fabiana Infante</au><au>Sieczkowska, Sofia Mendes</au><au>Aikawa, Nádia Emi</au><au>Pasoto, Sandra</au><au>Medeiros‐Ribeiro, Ana Cristina</au><au>Saad, Carla</au><au>Yuk, Emily</au><au>Silva, Clovis</au><au>Swinton, Paul</au><au>Hallal, Pedro Curi</au><au>Roschel, Hamilton</au><au>Bonfa, Eloisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients</atitle><jtitle>Scandinavian journal of medicine & science in sports</jtitle><date>2022-10</date><risdate>2022</risdate><volume>32</volume><issue>10</issue><spage>1510</spage><epage>1515</epage><pages>1510-1515</pages><issn>0905-7188</issn><eissn>1600-0838</eissn><abstract>This prospective cohort study within an open‐label, single‐arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698) aimed to investigate the association between physical activity and persistent anti‐SARS‐CoV‐2 antibodies 6 months after two‐dose schedule of CoronaVac in autoimmune rheumatic diseases (ARD) patients (n = 748). Persistent immunogenicity 6 months after the full‐course vaccination was assessed using seroconversion rates of total anti‐SARS‐CoV‐2 S1/S2 IgG, geometric mean titers of anti‐S1/S2 IgG (GMT), and frequency of positive neutralizing antibodies (NAb). Physical activity was assessed trough questionnaire. Adjusted point estimates from logistic regression models indicated that physically active patients had greater odds of seroconversion rates (OR: 1.5 [95%CI: 1.1 to 2.1]) and NAb positivity (OR: 1.5 [95%CI: 1.0 to 2.1]), and approximately 43% greater GMT (42.8% [95%CI: 11.9 to 82.2]) than inactive ones. In conclusion, among immunocompromised patients, being physically active was associated with an increment in antibody persistence through 6 months after a full‐course of an inactivated SARS‐CoV‐2 vaccine.</abstract><cop>Oxford</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1111/sms.14213</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-0520-4681</orcidid><orcidid>https://orcid.org/0000-0001-9663-0696</orcidid><orcidid>https://orcid.org/0000-0001-7100-8681</orcidid><orcidid>https://orcid.org/0000-0001-9245-287X</orcidid><orcidid>https://orcid.org/0000-0003-4218-4779</orcidid><orcidid>https://orcid.org/0000-0003-1470-6461</orcidid><orcidid>https://orcid.org/0000-0002-9513-6132</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0905-7188 |
| ispartof | Scandinavian journal of medicine & science in sports, 2022-10, Vol.32 (10), p.1510-1515 |
| issn | 0905-7188 1600-0838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2691462504 |
| source | Access via Wiley Online Library |
| subjects | autoimmune rheumatic disease COVID‐19 Drug dosages Exercise immunosuppression physical activity vaccine responses |
| title | Physical activity and antibody persistence 6 months after the second dose of CoronaVac in immunocompromised patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T19%3A09%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physical%20activity%20and%20antibody%20persistence%206%20months%20after%20the%20second%20dose%20of%20CoronaVac%20in%20immunocompromised%20patients&rft.jtitle=Scandinavian%20journal%20of%20medicine%20&%20science%20in%20sports&rft.au=Gualano,%20Bruno&rft.date=2022-10&rft.volume=32&rft.issue=10&rft.spage=1510&rft.epage=1515&rft.pages=1510-1515&rft.issn=0905-7188&rft.eissn=1600-0838&rft_id=info:doi/10.1111/sms.14213&rft_dat=%3Cproquest_cross%3E2713150780%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2713150780&rft_id=info:pmid/&rfr_iscdi=true |